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Urinary tract infections (UTIs) are among the most common infectious diseases of humans, with Escherichia
coli being responsible for >80% of all cases. Asymptomatic bacteriuria (ABU) occurs when bacteria colonize
the urinary tract without causing clinical symptoms and can affect both catheterized patients (catheter-
associated ABU [CA-ABU]) and noncatheterized patients. Here, we compared the virulence properties of a
collection of ABU and CA-ABU nosocomial E. coli isolates in terms of antibiotic resistance, phylogenetic
grouping, specific UTI-associated virulence genes, hemagglutination characteristics, and biofilm formation.
CA-ABU isolates were similar to ABU isolates with regard to the majority of these characteristics; exceptions
were that CA-ABU isolates had a higher prevalence of the polysaccharide capsule marker genes kpsMT II and
kpsMT K1, while more ABU strains were capable of mannose-resistant hemagglutination. To examine biofilm
growth in detail, we performed a global gene expression analysis with two CA-ABU strains that formed a strong
biofilm and that possessed a limited adhesin repertoire. The gene expression profile of the CA-ABU strains
during biofilm growth showed considerable overlap with that previously described for the prototype ABU E. coli
strain, 83972. This is the first global gene expression analysis of E. coli CA-ABU strains. Overall, our data
suggest that nosocomial ABU and CA-ABU E. coli isolates possess similar virulence profiles.
Urinary tract infections (UTIs) are among the most common
infectious diseases acquired in nosocomial settings. UTIs may
be symptomatic (e.g., cystitis and pyelonephritis) or asymptom-
atic. Asymptomatic bacteriuria (ABU) is an asymptomatic car-
rier state that resembles commensalism. ABU patients often
carry 105 CFU/ml of urine of a single bacterial strain without
symptoms; in nosocomial settings, ABU frequently occurs in
both catheterized and noncatheterized patients. In catheter-
ized patients, the risk of bacteriuria is estimated to be 5 to 10%
per day (46), and most patients with an indwelling urinary
catheter for 30 days or longer develop bacteriuria (35). ABU in
catheterized and noncatheterized patients may also lead to
symptomatic UTIs, with patients experiencing fever, suprapu-
bic tenderness, and, in some cases, bacteremia, acute pyelone-
phritis, and death (16, 45).
ABU is caused by a range of Gram-negative and Gram-
positive organisms, including Escherichia coli, Proteus mirabilis,
Pseudomonas aeruginosa, Providencia stuartii, Staphylococcus
epidermidis, and Enterococcus faecalis (16, 46). In many cases,
the bacteria that cause these infections are resistant to multiple
antibiotics, and thus, they pose a serious threat to the safety
and proper functioning of health care facilities. E. coli is one of
the most common causes of nosocomial UTIs (including ABU)
(17, 36). Many ABU E. coli strains are phylogenetically related
to virulent uropathogenic E. coli (UPEC) strains, with the
differences in virulence properties being multifactorial and as-
sociated with various combinations of genotypic and pheno-
typic factors (26, 49). The prototype ABU E. coli strain, strain
83972, is a B2 clinical isolate capable of long-term bladder
colonization, as shown in human inoculation studies (14, 38).
Bladder infection with E. coli 83972 fails to induce a host
inflammatory response, and this is associated with the attenu-
ation of several virulence determinants, including type 1, P,
and F1C fimbriae (24, 32, 47). The lack of fimbriae appears to
be essential, as a P-fimbriated and adherent transformant of E.
coli 83972 triggers inflammation in the human urinary tract
(47).
The characteristics of E. coli that cause asymptomatic bacteri-
uria in catheterized patients (catheter-associated ABU [CA-
ABU]) and their relationship to ABU E. coli in noncatheter-
ized patients have not been investigated. The insertion and
presence of an indwelling catheter predispose an individual to
infection by causing damage to the uroepithelial mucosa and
providing a surface for biofilm formation, which may thus
affect the normal functioning and voiding of the bladder (7,
16). Therefore, E. coli strains causing asymptomatic bacteriuria
in noncatheterized and catheterized patients may utilize dif-
ferent strategies to efficiently colonize the urinary tract. In the
present study, we have compared the molecular characteristics,
phenotypic properties and antimicrobial resistance profiles of
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176 consecutively isolated ABU E. coli strains (from noncath-
eterized patients) and CA-ABU E. coli strains from the same
geographic area. Biofilm formation was identified as a com-
mon feature for both ABU and CA-ABU strains, and we
explored this further by examining the transcriptome of two
CA-ABU E. coli strains during biofilm growth and comparing
this with the transcriptome for ABU E. coli 83972 grown under
the same conditions.
MATERIALS AND METHODS
Patients and bacterial isolates. Eighty-eight E. coli ABU isolates and 88 E. coli
CA-ABU isolates were obtained from urine samples of patients at the Princess
Alexandra Hospital (Brisbane, Queensland, Australia) during the period from
February to July 2006. ABU was defined as a clean-catch voided urine specimen
with counts of 105 CFU/ml of a single organism. There were no ABU patients
who were catheterized. CA-ABU was defined by the presence of an indwelling
catheter and a urine specimen with counts of 105 CFU/ml. ABU and CA-ABU
patients had no conditions indicative of symptomatic UTIs (i.e., fever, suprapu-
bic tenderness, or costovertebral angle tenderness) in the 48-h period prior to or
following urine collection. ABU patients (67% female) had a mean age of 66
years (range, 20 to 100 years); CA-ABU patients (46% female) had a mean age
of 56 years (range, 17 to 94 years). The most common comorbid conditions were
23% endocrine, 19% cardiovascular dysfunction, 16% neurological, and 15%
urological for patients with ABU and 51% neurological, 22% endocrine, 15%
urological, 7% musculoskeletal, and 7% cardiovascular dysfunction for patients
with CA-ABU. Urine cultures were performed as part of ward screening. All E.
coli isolates were identified by typical morphology, lactose fermentation, and a
positive spot indole test. Isolates that did not meet these criteria were identified
in full by a Vitek 2-GN card (bioMe´rieux). Isolates were tested for resistance to
common antimicrobial agents using the Vitek 2 system at the Princess Alexandra
Hospital. E. coli 83972 is a prototype ABU clinical isolate originally isolated from
a young Swedish girl who carried it for 3 years without adverse affects (1a, 25).
All strains were routinely grown at 37°C on solid or in liquid Luria-Bertani (LB)
medium.
PCR screening. The presence of the following virulence genes was assessed for
each ABU and CA-ABU isolate: fimH (type 1 fimbrial adhesin), papG I to III (P
fimbriae adhesins), flu (antigen 43), focG (F1C fimbrial subunit protein), sfaS (S
fimbrial adhesin), afa/draBC (Afa/Dr chaperone and anchoring proteins), mrkB
(type 3 fimbrial chaperone protein), hlyA (hemolysin), cnf1 (cytotoxic necrotizing
factor 1), fyuA (yersiniabactin receptor), iutA (aerobactin receptor), iroN (sal-
mochelin receptor), kpsMT II (group II capsule), kpsMT III (group III capsule),
kpsMT K1 (K1 capsule), and kpsMT K5 (K5 capsule). The methods for bacterial
DNA preparation, primer sequences, and reaction conditions have been de-
scribed previously (22, 23, 29, 42). The E. coli phylogenetic group of origin was
determined using a three-locus PCR-based method (4). All strains were tested in
duplicate with appropriate positive and negative controls.
Phenotypic assays. The capacity of bacteria to express type 1 fimbriae was
assayed by determining their ability to agglutinate yeast cells on glass slides (34).
Those strains that reacted negative in this assay were retested after three suc-
cessive rounds of 48 h of static growth in LB medium. Mannose-resistant hem-
agglutination (MRHA) was assessed as described previously (9). Hemolysin
production was detected on sheep blood agar plates as described previously (21).
Strains that produced a clear zone of lysis after incubation for 24 h at 37°C were
considered positive. Motility was assayed by inoculating 0.25% LB agar plates
with 2 l of overnight liquid cultures and measuring the diameter of bacterial
growth 16 h after inoculation.
Biofilm assays. For screening of the isolate collection, biofilm formation on
polyvinyl chloride (PVC) surfaces was monitored using 96-well microtiter plates
(Falcon), following growth in synthetic urine, as described previously (26). Iso-
lates were considered positive for biofilm formation if the stained biofilm had an
absorbance at 595 nm equal to or greater than 0.5. The results represent the
averages of three independent experiments, each with four replicates per strain.
E. coli M366 and MS2034 and their respective ybtS deletion mutants were
assayed for biofilm formation in the same manner. Biofilm growth on Bard
Biocath Foley latex catheters was assayed for 10 ABU and 10 CA-ABU strains
selected as representatives for the different levels of biofilm growth observed on
the PVC microtiter plates. The strains were grown statically for 24 h at 37°C in
3 ml of pooled human urine in the presence of a catheter section (1 cm long,
vertically dissected). The urine was then removed and replaced with fresh pooled
human urine from the same original source, and the incubation was continued as
described above for a further 24 h. Following this incubation, the catheter
sections were removed, washed twice with phosphate-buffered saline (PBS) and
transferred to 1 ml sterile PBS, and the biofilm was disrupted by vigorous
vortexing using a TissueLyser (Qiagen). The bacteria were enumerated using
quantitative colony counts on agar to determine the amount of biofilm growth.
All experiments were repeated at least twice.
Microarray experiments. DNA microarrays were performed for CA-ABU E.
coli strains M366 and MS2034, as described previously (11). Briefly, M366 and
MS2034 were grown to mid-exponential phase in morpholinepropanesulfonic
acid (MOPS) minimal medium (supplemented with 0.2% glucose) or pooled
human urine or as a biofilm in urine in 94-mm petri dishes (Greiner Bio-One).
Each combination of strain and growth condition was assayed in triplicate.
Samples for RNA isolation were extracted and mixed directly with 2 volumes of
RNAprotect bacterial reagent (Qiagen AG). Total RNA was isolated, and on-
column DNase digestion was performed using an RNeasy minikit and an RNase-
free DNase set (Qiagen AG). Purified RNA (10 g per sample) was converted
to cDNA, and microarray analysis was performed according to the guidelines of
the GeneChip Expression Analysis Technical Manual 701023, revision 4 (Af-
fymetrix Inc., Santa Clara, CA) (1). Labeled cDNA was hybridized to GeneChip
E. coli Genome 2.0 arrays (Affymetrix). Overall, nine samples were hybridized to
nine chips for each strain, with triplicates for the three growth conditions being
used. Hybridization, washing, and staining were performed as described in the
GeneChip Expression Analysis Technical Manual 701023 (1), with the microarrays
being scanned using a GeneChip Scanner 3000 scanner. The 18 arrays for strains
M366 and MS2034 were normalized with the E. coli 83972 arrays previously
analyzed under the same growth conditions (11, 33). Data analysis was per-
formed as described previously (11). For each strain, the fold changes were
calculated for biofilm growth compared to either planktonic growth in MOPS or
planktonic growth in urine. Randomly permuting the samples 200 times gave
false discovery rates of 0.0 to 0.7% (1 to 22 false-positive genes) for the different
comparisons.
Construction of ybtS deletion mutants. Deletion mutants of the yersiniabactin
synthesis gene ybtS in strains M366 and MS2034 were constructed using the
bacteriophage  red recombinase gene inactivation method, as described previ-
ously (5). Plasmid pKD4 was used as the template with the deletion primers
previously employed by Henderson et al. (12). The PCR product was trans-
formed into M366(pKD46) and MS2034(pKD46), respectively, and mutants
were selected following growth on LB agar containing kanamycin (50 g/ml).
Deletion mutants were verified by PCR with the ybtS flanking primers 5-GCA
CCGCCTTATACAATTGG and 5-GTTATCGGTGGCGTTGTTG.
Statistical analysis. Comparisons of prevalence data were tested using the 2
test and Fisher’s exact test with MiniTab (version 15) statistical software. The
median virulence scores were compared using the Mann-Whitney U test. Dif-
ferences in catheter biofilm growth were tested using a Student t test. The level
of statistical significance was set at P  0.05.
Microarray data accession number. The microarray data have been deposited
in Array Express (http://www.ebi.ac.uk/arrayexpress) under accession number
E-MEXP-2298.
RESULTS
Phylogenetic grouping of ABU and CA-ABU strains. Our
collection comprised 88 ABU and 88 CA-ABU E. coli strains
isolated from the same geographic location. The majority of
the strains belonged to phylogenetic group B2 (68% versus 8%
for group A, 5% for group B1, and 19% for group D) (Table
1). The distribution of phylogenetic groups did not differ sig-
nificantly between the ABU and CA-ABU strains (for ABU
strains, 8% A, 6% B1, 68% B2, and 18% D; for CA-ABU
strains, 9% A, 3% B1, 68% B2, and 19% D).
Resistance to antibacterial agents. We compared the antibio-
gram of each ABU and CA-ABU E. coli strain by examining
for resistance to ampicillin, ceftazidime, cephalothin, cefazolin,
ciprofloxacin, ceftriaxone, cefepime, cefoxitin, gentamicin, cepha-
lexin, meropenem, nitrofurantoin, norfloxacin, trimethoprim-
sulfamethoxazole, trimethoprim, tobramycin, and piperacillin-
tazobactam. There was no significant difference in the number
of ABU and CA-ABU strains resistant to each antibiotic (Fig.
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1). The antibiotics to which there was most commonly resis-
tance were cephalothin (57% of all strains) and ampicillin
(49% of all strains); 32% of the strains were susceptible to all
of the antibiotics tested.
Distribution of virulence genes. The prevalence of 18 de-
fined virulence marker genes in the 176 ABU and CA-ABU E.
coli strains was assessed by PCR (Table 1). The median num-
bers of virulence genes for the ABU and CA-ABU strains were
similar: five and six, respectively. The fimH gene was the most
common virulence gene and was present in 98% of both ABU
and CA-ABU strains. The papG gene was detected in 42% of
ABU strains and 43% of CA-ABU strains. Genes for F1C
fimbriae, S fimbriae, and the Afa/Dr family of adhesins were
present in 8 to 23% of strains, with similar numbers observed
for ABU and CA-ABU strains. The gene encoding the auto-
transporter adhesin Ag43 (flu) was present in 60% of all
strains, and the distributions were similar among the ABU and
CA-ABU groups. Genes encoding the UPEC toxins hemolysin
(hlyA) and cytotoxic necrotizing factor 1 (cnf1) were also found
in similar numbers in ABU strains (19% hlyA positive, 27%
cnf1 positive) and CA-ABU strains (27% hlyA positive, 26%
cnf1 positive). Several siderophore receptor-encoding genes
were examined; the fyuA gene (encoding the yersiniabactin
receptor) was the most prevalent (78% of ABU strains, 83% of
CA-ABU strains), while the iutA (encoding the aerobactin
receptor) and iroN (encoding the salmochelin receptor) genes
were present in 35 to 50% of ABU and CA-ABU strains (the
differences were not significant). The only statistically signifi-
cant differences in prevalence were observed for the kpsMT II
gene, specific for group II capsule biosynthesis, and the kpsMT
K1 gene, which were more frequently associated with CA-
ABU isolates than with ABU isolates (P  0.005 and P 
0.002, respectively). Overall, the virulence factor loads of iso-
lates from both the ABU and CA-ABU groups were similar.
The median numbers of virulence factors for each phylogenetic
group were as follows: for ABU strains, three virulence factors
for group A, two for B1, seven for B2, and four for D; for
CA-ABU strains, two virulence factors for group A, one for
B1, seven for B2, and six for D.
Distribution of virulence genes among ampicillin- and ceph-
alothin-resistant strains. Ampicillin and cephalothin were the
antibiotics to which the E. coli strains examined in this study
were most commonly resistant. There was a significant differ-
ence in the median number of virulence factors between am-
picillin-resistant and ampicillin-susceptible CA-ABU strains
(six versus four; P  0.017). Ampicillin-resistant CA-ABU E.
coli had a significantly higher prevalence of the papG, flu, iutA,
and kpsMT K5 virulence genes (Table 1). There was no differ-
ence in the median number of virulence factors between am-
picillin-resistant and ampicillin-susceptible ABU strains. The
comparison between cephalothin-resistant ABU and CA-ABU
strains revealed the opposite distribution: the median numbers
of virulence factors for cephalothin-resistant and cephalothin-
susceptible ABU strains were 4 and 7, respectively (P 0.004),
while there was no difference between cephalothin-resistant and
cephalothin-susceptible CA-ABU strains. Genes found more
commonly in cephalothin-susceptible strains than in cephalothin-
resistant strains included papG, focG, hlyA, cnf1, and iroN.
Phenotypic characterization of ABU and CA-ABU strains.
Many UTI E. coli strains carry virulence genes but fail to
express the associated phenotype (26). Phenotypic assays were
therefore performed to assess the expression of type 1 fim-
briae, P fimbriae, and hemolysin (Table 1). The majority of
fimH-positive ABU and CA-ABU strains agglutinated yeast
cells (95% and 94%, respectively), demonstrating functional
type 1 fimbrial expression. MRHA can be promoted by several
different fimbrial types, including P, S, G, and M fimbriae, as
well as the Afa/Dr family of adhesins (19). A higher percentage
of ABU strains than CA-ABU strains showed an MRHA phe-
notype (34% and 15%, respectively; P  0.003). More strains
FIG. 1. Numbers of ABU and CA-ABU E. coli isolates resistant to each antibiotic included in the antibiotic screening. The “none” category
indicates isolates that were susceptible to all antibiotics included in this study. There were no statistically significant differences between the
numbers of resistant isolates in the ABU and CA-ABU groups for any antibiotic. AMP, ampicillin; CAZ, ceftazidime; CEF, cephalothin; CFZ,
cefazolin; CIP, ciprofloxacin; CRO, ceftriaxone; FEP, cefepime; FOX, cefoxitin; GEN, gentamicin; LEX, cephalexin; MEM, meropenem; NIT,
nitrofurantoin; NOR, norfloxacin; SXT, trimethoprim-sulfamethoxazole; TMP, trimethoprim; TOB, tobramycin; and TZP, piperacillin-tazobactam.
2452 WATTS ET AL. J. CLIN. MICROBIOL.
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
contained the papG allele than expressed the associated
MRHA phenotype: 65% ABU and 29% CA-ABU papG-pos-
itive strains expressed MRHA (P  0.002). Hemolysin assays
were also performed to determine if strains possessing hlyA
were hemolytic. Three hlyA-positive strains were nonhemo-
lytic, while four strains that screened negative for hlyA were
hemolytic. There was no significant difference in the number of
hemolytic ABU strains (20%) and CA-ABU strains (18%).
Biofilm formation. The ability of each ABU and CA-ABU
E. coli isolate to form a biofilm was assessed using the micro-
titer plate biofilm assay. The CA-ABU strains displayed no
significant difference from the ABU strains in the biofilm for-
mation phenotype; 48% of CA-ABU and 59% of ABU strains
formed a biofilm (Table 1). The mean biofilm formation values
were similar for the ABU and CA-ABU groups (0.58 versus
0.54; P  0.391) (Fig. 2). To examine how these results com-
pared with biofilm formation on a catheter surface, we selected
10 ABU and 10 CA-ABU strains that encompassed the range
of biofilm formation observed on PVC microtiter plates and
examined their biofilm formation phenotype using a catheter
biofilm assay. Under these experimental conditions, all of the
ABU strains formed a biofilm equivalent to that produced by
the prototype ABU E. coli strain, 83972 (Fig. 3). In contrast,
four of the CA-ABU strains showed significantly higher levels
of biofilm growth on the catheter surface than E. coli 83972
(P  0.05) (Fig. 3).
Global gene expression of CA-ABU E. coli strains during
biofilm formation. To examine the similarities between the
ABU and CA-ABU strains further, two CA-ABU strains
(M366 and MS2034) with a limited repertoire of known ad-
hesins and biofilm growth similar to that of prototype ABU E.
coli strain 83972 were selected for further analysis (Table 2;
Fig. 2). We examined the global gene expression profile of E.
coli M366 and MS2034 during biofilm growth in pooled human
urine as well as during planktonic growth in pooled human
FIG. 2. Biofilm formation of ABU and CA-ABU E. coli isolates in
synthetic urine. Strains were grown in PVC microtiter plates, washed,
and stained with 0.1% crystal violet. The absorbance at 595 nm cor-
relates to the amount of biofilm formed. The results are the averages
of three independent experiments, each with four replicates. Horizon-
tal bars indicate the mean for each infection category. The CA-ABU E.
coli isolates selected for transcriptome analysis (M366 and MS2034)
and the relative position of ABU E. coli strain 83972 are indicated.
FIG. 3. Biofilm formation of selected ABU and CA-ABU E. coli isolates on Foley latex catheters. Catheter sections were incubated with isolates
in human urine, and biofilm formation was assessed via colony counting. Biofilm formation as the number of CFU per 1-cm catheter section was
standardized to that of ABU E. coli strain 83972. The results are the averages of at least duplicates, with error bars indicating standard deviations.
The four CA-ABU isolates which had significantly higher levels of biofilm growth than ABU E. coli 83972 are marked with asterisks (P  0.05).
The corresponding amount of biofilm growth for each strain on PVC microtiter plates is also indicated and expressed as either low (), medium
(	), or high (		).
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urine and in MOPS minimal medium. We then compared
these data with those previously obtained for E. coli 83972
grown under the same conditions (11, 33).
Transcriptomic analysis of M366 and MS2036 revealed that
there was considerable overlap with E. coli 83972 in the genes
up- or downregulated during biofilm growth versus planktonic
growth in urine and MOPS minimal medium (Fig. 4). Com-
paring biofilm and planktonic growth in urine, 69% and 57%
of the upregulated genes in M366 were also upregulated in
MS2034 and 83972, respectively; under the same conditions,
77% and 57% of the downregulated M366 genes were shared
with MS2034 and 83972, respectively. Overall, the three strains
shared 443 genes significantly upregulated and 498 genes
downregulated during biofilm growth in urine compared to the
level of gene expression during planktonic growth in urine
(data not shown). The three strains also shared 420 genes
significantly upregulated and 709 genes downregulated during
biofilm growth in urine compared to the level of gene expres-
sion during planktonic growth in MOPS (data not shown). The
majority of the top 50 upregulated genes of E. coli M366
during biofilm growth compared to the level of gene expression
during planktonic growth were also upregulated in strains
MS2034 and 83972. These genes included those encoding cold
and heat shock proteins, transcriptional regulators, enzymes,
putative transport proteins, and iron uptake proteins.
We also compared the gene expression profiles of M366,
MS2034, and 83972 according to functional group classifica-
tions (Table 3). The two CA-ABU strains had similar numbers
of genes up- or downregulated as ABU strain 83972 for most
functional groups. The most upregulated functional groups
were transcription, intracellular trafficking and secretion, and
signal transduction mechanisms. In contrast, the most down-
regulated functional groups were translation; amino acid trans-
port and metabolism; and secondary metabolite biosynthesis,
transport, and catabolism.
Upregulation of genes involved in iron uptake. We specifi-
cally examined the transcription of genes involved in iron up-
take by E. coli M366 and MS2034 during biofilm growth in
urine and compared this to transcription during planktonic
growth in MOPS minimal medium (Fig. 5). We observed a
consistent pattern of increased gene expression, with the most
strongly expressed genes being associated with the enterobac-
tin, SitABCD, and yersiniabactin pathways (for example, 12/19
yersiniabactin genes and sitA were in the top 50 upregulated
genes of M366 during biofilm formation compared to the gene
expression during planktonic growth in MOPS). We next com-
pared these data with the transcription profile for E. coli 83972
grown under the same conditions. Unlike E. coli 83972, E. coli
M366 and MS2034 did not express the genes encoding aero-
bactin synthesis, which is consistent with our PCR typing of
these strains as iutA negative. E. coli M366 was also iroN
negative, and we did not detect transcription of the iroBCDEN
genes. However, a major difference between the M366 and
MS2034 CA-ABU strains and ABU E. coli strain 83972 was the
level of expression of the yersiniabactin genes. Most of the
FIG. 4. Numbers of significantly up- and downregulated genes of E.
coli strains 83972, M366, and MS2034 during biofilm growth compared
to the level of gene expression during planktonic growth in urine
(A) and MOPS minimal medium (B).
TABLE 2. Characteristics of CA-ABU E. coli isolates selected for
transcriptome analysis compared with those of ABU
E. coli strain 83972a
Characteristic M366 MS2034 83972
Adhesins
fimH 	 	 NF
papG I   
papG II   
papG III   NF
flu   	
focG   NF
sfaS   
afa/draBC   
mrkB   
Toxins
hlyA  	 NF
cnf1  	 	
Iron uptake systems
fyuA 	 	 	
iutA   	
iroN  	 	
Capsular types
kpsMT II 	 	 	
kpsMT III   
kpsMT K1 	 	 
kpsMT K5   	
Agglutination
Yeast 	 	 
MRHA   
Hemolysis   
Biofilm formation on PVC 	 	 	
Motility 	 	 
Antibiotic resistance CEF AMP/CEF 
a All three strains are phylogenetic group B2. Abbreviations: NF, nonfunc-
tional; CEF, cephalothin; AMP, ampicillin.
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genes involved in the yersiniabactin biosynthetic pathway, as
well as the fyuA receptor-encoding gene, were significantly
upregulated in E. coli M366 and MS2034 compared to the level
of expression in E. coli 83972 (Fig. 5). To examine if the
biosynthesis of yersiniabactin affected biofilm formation, we
deleted the ybtS gene from E. coli M366 and MS2034. There
was no difference in biofilm growth between wild-type and ybtS
mutant strains, suggesting that while the level of transcription
of the yersiniabactin biosynthesis genes was increased, this was
not an absolute requirement for biofilm growth by E. coli M366
and MS2034 under the experimental conditions employed.
DISCUSSION
In the present study, we compared E. coli strains that cause
ABU and CA-ABU for differences in phylogenetic group, an-
tibiotic resistance, virulence factors, and phenotypic properties
(including biofilm formation). We then selected two CA-ABU
strains and examined their global gene expression profile dur-
ing biofilm growth in urine and compared this to the profile for
the prototype ABU E. coli strain 83972.
Our analysis revealed that the majority of the ABU and
CA-ABU strains belonged to phylogenetic groups B2 and D.
These phylogenetic groups are most commonly associated with
extraintestinal pathogenic E. coli (2, 23, 30, 39). In support of
this typing, we also observed a widespread occurrence of vir-
ulence factors for ABU and CA-ABU strains. Of the 18 UTI-
associated virulence genes examined, there was a similar prev-
alence rate for all genes except the group II capsule-specific
kpsMT II gene and the K1 capsule marker gene kpsMT K1,
which were more prevalent within CA-ABU strains. This differ-
ence may reflect polysaccharide production during catheter col-
onization and biofilm growth by CA-ABU strains. Although there
was no increased expression of capsule genes during biofilm
growth in vitro for CA-ABU isolates M366 and MS2034, capsule
production may be increased during host infection.
An interesting finding in our study was the observation
that ABU and CA-ABU strains displayed very similar pro-
files with respect to antibiotic resistance. Ampicillin, cephalothin,
trimethoprim, and trimethoprim-sulfamethoxazole were the anti-
biotics to which resistance was most commonly detected. This is
consistent with the use of these antibiotics to treat nosocomial
and community-acquired UTIs. The low levels of resistance to
gentamicin and quinolone antibiotics reflect their restricted use in
Australia. Previous studies have epidemiologically linked anti-
microbial resistance in extraintestinal pathogenic E. coli strains
with reduced inferred virulence, often due to a decreased prev-
alence of phylogenetic group B2 within antimicrobial-resistant
strains (20, 37, 44). In our study, cephalothin-resistant ABU
strains had a lower median number of virulence factors and a
decreased prevalence of phylogenetic group B2 compared to
the cephalothin-susceptible ABU strains. However, analysis of
group B2 ABU strains independently revealed that the differ-
ence in phylogenetic grouping between resistant and suscepti-
ble strains did not account for the difference in inferred viru-
lence (five and seven median virulence factors for group B2
cephalothin-resistant and -susceptible strains, respectively; P
0.016). Interestingly, resistance to ampicillin among the CA-
ABU strains followed a reverse trend with respect to the me-
TABLE 3. Numbers of significantly up- and downregulated E. coli MG1655 genes in each functional group for the E. coli strains during
biofilm growth in urine compared to the level of expression during planktonic growth in urine
Functional group
No. (%) of genesa
Upregulated genes in biofilm Downregulated genes in biofilm
Total
M366 MS2034 83972 M366 MS2034 83972
Amino acid transport and metabolism 28 (9) 39 (13) 36 (12) 93 (31) 102 (34) 85 (29) 296
Carbohydrate transport and metabolism 39 (13) 40 (13) 37 (12) 81 (27) 94 (32) 90 (30) 298
Cell cycle control, mitosis, and meiosis 6 (19) 9 (29) 7 (23) 8 (26) 9 (29) 6 (19) 31
Cell motility 4 (4) 7 (8) 14 (15) 4 (4) 4 (4) 3 (3) 91
Cell wall/membrane biogenesis 25 (13) 28 (14) 28 (14) 45 (23) 54 (27) 37 (19) 200
Coenzyme transport and metabolism 22 (20) 24 (22) 23 (21) 16 (15) 24 (22) 16 (15) 108
Defense mechanisms 2 (6) 3 (9) 9 (26) 6 (17) 9 (26) 1 (3) 35
Energy production and conversion 25 (10) 21 (9) 32 (13) 71 (30) 84 (35) 74 (31) 240
Function unknown 45 (18 52 (21) 65 (26) 50 (20) 61 (25) 43 (17) 247
General function prediction only 48 (18) 45 (17) 68 (25) 48 (18) 61 (23) 42 (16) 269
Inorganic ion transport and metabolism 24 (15) 32 (20) 40 (25) 22 (14) 34 (21) 18 (11) 160
Intracellular trafficking and secretion 9 (25) 13 (36) 8 (22) 5 (14) 4 (11) 7 (19) 36
Lipid transport and metabolism 12 (17) 12 (17) 11 (15) 12 (17) 18 (25) 17 (24) 71
Nucleotide transport and metabolism 19 (24) 19 (24) 14 (18) 10 (13) 20 (26) 13 (17) 78
Posttranslational modification, protein
turnover, and chaperones
19 (16) 25 (21) 31 (26) 22 (18) 31 (26) 19 (16) 119
Replication, recombination, and repair 26 (16) 30 (18) 33 (20) 20 (12) 23 (14) 18 (11) 165
Secondary metabolites biosynthesis,
transport, and catabolism
4 (7) 5 (9) 5 (9) 16 (30) 20 (37) 16 (30) 54
Signal transduction mechanisms 19 (16) 19 (16) 37 (32) 19 (16) 28 (24) 11 (9) 116
Transcription 65 (28) 73 (31) 74 (31) 24 (10) 35 (15) 26 (11) 235
Translation 40 (26) 48 (31) 26 (17) 20 (13) 22 (14) 55 (35) 156
Not in COGsb 175 (16) 190 (18) 217 (20) 100 (9) 164 (15) 126 (12) 1,065
MG1655 (total of above genes) 656 (16) 734 (18) 815 (20) 692 (17) 901 (22) 723 (18) 4,070
a Values in boldface indicate the functional groups with the highest percentage of differentially regulated genes for each E. coli strain.
b COGs, clusters of orthologous groups.
VOL. 48, 2010 VIRULENCE PROPERTIES OF CA-ABU AND ABU E. COLI 2455
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
dian number of virulence factors (four versus six for suscepti-
ble and resistant strains, respectively). Overall, the relationship
between antimicrobial resistance and virulence in our isolate
collection varied not only with the antimicrobial agent but also
with the strain clinical origin.
Since UTI E. coli strains may possess virulence genes but fail
to express the associated phenotype, several virulence-related
phenotypes were examined. ABU and CA-ABU E. coli strains
differed only with regard to MRHA, possibly due to the de-
creased number of papG-positive CA-ABU strains capable of
MRHA under the conditions used for testing. While P fimbriae
are not associated with persistence in healthy or catheterized
urinary tracts, they have been shown to enhance the establish-
ment of bacteriuria by ABU strain 83972 (1a, 28, 48). Type 1
fimbriae, as determined by yeast agglutination, were expressed
by the majority of the ABU and CA-ABU E. coli strains. This
fimbrial type, unlike P fimbriae, is associated with catheter
colonization and persistence in the catheterized urinary tract
(28, 41). Furthermore, the introduction of a plasmid containing
type 1 fimbrial genes increased catheter adherence of ABU
strain 83972 up to 100-fold and improved its ability to prevent
colonization by pathogenic E. coli (41).
CA-ABU results from the growth of bacterial biofilms on
the inner surface of the urinary catheter. Although the molec-
ular mechanisms of biofilm formation by E. coli in the cathe-
terized urinary tract are not fully understood, surface adhesins
such as type 1 fimbriae, type 3 fimbriae, and curli have been
shown to contribute to biofilm growth (28, 29, 41, 43). In
contrast, ABU E. coli strains are often associated with poor
epithelial cell adhesion properties, and thus, the role of biofilm
growth in colonization by these strains is less clear. Despite
this, we found that the ABU and CA-ABU E. coli strains
examined in this study possessed similar biofilm formation
properties, as assessed by the PVC microtiter plate assay. Fur-
thermore, we did not observe any significant difference in the
adhesin gene repertoires of the ABU and CA-ABU strains. It
FIG. 5. Fold changes in the levels of expression of iron acquisition genes of E. coli strains 83972, M366, and MS2034 during biofilm growth in
urine compared to the levels during planktonic growth in MOPS minimal medium.
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is possible that some ABU strains form biofilms within the
bladder without invoking host responses through direct attach-
ment to mucosal cell receptors or that biofilm growth in the
urinary tract leads to reduced virulence gene expression and
thus a decreased interaction with the host. Indeed, we previ-
ously found several ABU strains able to adhere to bladder
epithelial cells without provoking a cytokine response (26).
To examine biofilm growth in more detail, we also tested a
representative selection of ABU and CA-ABU strains for their
ability to form a biofilm on a catheter surface in pooled human
urine. All of the ABU strains formed a biofilm similar to that
formed by E. coli 83972 in this assay. Among the CA-ABU
strains examined, four strains displayed a significant increase in
the level of biofilm formation relative to that of E. coli 83972.
We have previously reported that E. coli strains which cause
symptomatic and asymptomatic infections display different bio-
film formation phenotypes in human urine on polystyrene mi-
crotiter plates and catheter surfaces (6). The results presented
here suggest that while there is some degree of congruence
between these two assays, some differences are also apparent
at the strain level.
We further examined biofilm formation for selected CA-ABU
strains using global gene expression analysis with comparison
to the gene expression of prototype ABU E. coli strain 83972.
The two CA-ABU strains (M366 and MS2034) selected were
from the same phylogenetic group as ABU 83972 and also had
a limited adhesin repertoire. There was a significant overlap in
the genes up- or downregulated during biofilm growth com-
pared to the gene expression during planktonic growth for the
three E. coli strains, with 420 to 709 genes being shared be-
tween the three strains, depending on the comparison.
We focused on the transcription of genes involved in iron
uptake, since free iron is strictly limited in the urinary tract.
Efficient iron uptake has been suggested to be a mechanism by
which ABU strains grow in urine and are maintained in the
bladder (31, 33). One widespread method for iron acquisition
is the production of siderophores, low-molecular-mass iron-
chelating compounds, and their associated membrane recep-
tors (27). We examined the transcription of genes involved in
iron uptake by CA-ABU E. coli M366 and MS2034 with com-
parison to the transcription by ABU strain 83972. The majority
of these genes were upregulated during biofilm growth com-
pared to their level of expression during planktonic growth in
MOPS minimal medium for all three E. coli strains. Most
notably, the genes involved in the synthesis and transport of
the siderophore yersiniabactin (including the receptor-encod-
ing fyuA gene) were upregulated up to 88-fold in strains M366
and MS2034, with smaller changes (up to 9-fold) occurring in
strain 83972. Increased expression of the yersiniabactin path-
way genes has previously been shown for ABU E. coli 83972
and VR50 during biofilm formation (10, 11) and for E. coli
83972 during colonization of the human urinary tract (31).
Additionally, the yersiniabactin receptor FyuA is required for
efficient biofilm formation by strains 83972 and VR50 in urine
(10). However, when the yersiniabactin synthesis gene, ybtS,
was deleted in strains M366 and MS2034, no change in biofilm
growth was observed. Although the siderophore yersiniabactin
appears to be important for biofilm formation by ABU strain
83972, this was not seen in the CA-ABU strains examined
here. Of note also is the fact that E. coli 83972 is unable to
express type 1, P, and F1C fimbriae (24, 32). In contrast, 93%
and 34% of the ABU isolates in the present study expressed
type 1 and MRHA fimbriae, respectively. This suggests that E.
coli 83972 may use a different than that utilized strategy to
colonize the urinary tract by other ABU strains.
Overall, the E. coli ABU and CA-ABU isolates in our col-
lection had similar virulence profiles. Previous studies have
compared the virulence properties of E. coli ABU isolates in
noncatheterized patients to those of fecal isolates and isolates
from patients with other clinical syndromes, including cystitis
and pyelonephritis. Urinary isolates, including ABU E. coli,
typically have higher inferred virulence than fecal isolates from
healthy individuals (3, 18). Pyelonephritis isolates display the
most consistent differences in virulence properties from those
of ABU isolates, specifically, a higher prevalence of P-fimbrial
genes and an increased ability to cause MRHA (18, 26). There
is limited research on the virulence properties of E. coli isolates
colonizing the catheterized urinary tract, despite the high num-
bers of catheterized patients and the high risk of developing
bacteriuria once one is catheterized. The catheter literature
has also been complicated by the lack of differentiation
between bacterial isolates causing CA-ABU and catheter-
associated symptomatic urinary tract infection (CAUTI),
with guidelines recently being published to rectify this (13,
40). Comparative studies have been carried out mainly with
patients with bladder dysfunction and intermittent catheteriza-
tion where there were limited or no differences between the E.
coli strains causing asymptomatic and symptomatic infections
(8, 15). Since the insertion and presence of an indwelling
catheter substantially change the urinary tract environment, we
compared the virulence properties of E. coli isolates causing
asymptomatic bacteriuria in catheterized and noncatheterized
patients. An indwelling catheter predisposes an individual to
infection by introducing bacteria into the bladder, causing
damage to the uroepithelial mucosa, and providing a surface
for biofilm formation and can also affect normal functioning
and voiding of the bladder (7, 16). Despite this, we found little
difference in the virulence properties between the E. coli ABU
and CA-ABU isolates.
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